Company intelligence / Profile preview
Biostax
Orlando, Florida, United Statesbiostaxcorp.com ↗
- Ownership
- Private
- Employees
- ~4
- Development stage
- Other
01
Overview
Biostax has commercialized Lodonal in Nigeria for HIV/AIDS with clinical data showing a 44% increase in CD4 count versus standard of care and reduced opportunistic infections. JKB‑122 is an investigational TLR4 antagonist with preclinical anti-fibrotic and immunomodulatory activity targeting autoimmune hepatitis and NASH. The company is also developing digital health solutions using blockchain technology
- Therapeutic areas
- NeurologyInfectious DiseasesGastroenterologyOncologyOtherImmunology
- Modalities
- Small moleculeImmune system regulator (biologic/small molecule, e.g., Lodonal)Digital health technology (blockchain for health records)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
Partnerships in autoimmunity and immune restoration fields; details not specified
Beyond the preview
Go deeper on Biostax.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Biostax.